AVNS Stock - Avanos Medical, Inc.
Unlock GoAI Insights for AVNS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $687.80M | $673.30M | $684.10M | $744.60M | $714.80M |
| Gross Profit | $381.30M | $379.70M | $394.20M | $379.90M | $390.60M |
| Gross Margin | 55.4% | 56.4% | 57.6% | 51.0% | 54.6% |
| Operating Income | $40.00M | $65.00M | $41.90M | $86.80M | $70.90M |
| Net Income | $-392,100,000 | $-61,800,000 | $50.50M | $6.30M | $-27,200,000 |
| Net Margin | -57.0% | -9.2% | 7.4% | 0.8% | -3.8% |
| EPS | $-8.53 | $-1.33 | $1.08 | $0.13 | $-0.57 |
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 25th 2023 | KeyBanc Capital Markets | Downgrade | Sector Weight | - |
| May 22nd 2023 | CL King | Initiation | Buy | $31 |
Earnings History & Surprises
AVNSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.24 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.12 | $0.22 | +83.3% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.18 | $0.17 | -5.6% | ✗ MISS |
Q2 2025 | May 6, 2025 | $0.19 | $0.26 | +36.8% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.40 | $0.43 | +7.5% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $0.36 | $0.36 | 0.0% | = MET |
Q3 2024 | Jul 31, 2024 | $0.29 | $0.34 | +17.2% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $0.21 | $0.22 | +4.8% | ✓ BEAT |
Q1 2024 | Feb 20, 2024 | $0.37 | $0.36 | -2.7% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $0.29 | $0.30 | +3.4% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $0.34 | $0.24 | -29.4% | ✗ MISS |
Q2 2023 | May 3, 2023 | $0.28 | $0.27 | -3.6% | ✗ MISS |
Q1 2023 | Feb 21, 2023 | $0.48 | $0.60 | +25.0% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.35 | $0.38 | +8.6% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $0.39 | $0.41 | +5.1% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $0.24 | $0.26 | +8.3% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $0.40 | $0.46 | +15.0% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $0.27 | $0.25 | -7.4% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $0.23 | $0.21 | -8.7% | ✗ MISS |
Latest News
AVNS stock has given up its prior gain. Avanos Medical shares were trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 guidance above estimates.
➖ NeutralAvanos Medical shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 guidance above estimates.
📈 PositiveAvanos Medical Raises FY2025 Adj EPS Guidance from $0.75-$0.95 to $0.85-$0.95 vs $0.80 Est; Raises FY2025 Sales Guidance from $665.000M-$685.000M to $690.000M-$700.000M vs $676.000M Est
📈 PositiveAvanos Medical Raises FY2025 GAAP EPS Guidance from $0.33-$0.56 to $0.43-$0.56 vs $0.85 Est
➖ NeutralAvanos Medical Q3 Adj. EPS $0.22 Beats $0.12 Estimate, Sales $177.800M Beat $164.500M Estimate
📈 PositiveAvanos Medical To Sell US Game Ready Orthopedic Rental Operations To WRS Group; Financial Terms Not Disclosed
➖ NeutralFrequently Asked Questions about AVNS
What is AVNS's current stock price?
What is the analyst price target for AVNS?
What sector is Avanos Medical, Inc. in?
What is AVNS's market cap?
Does AVNS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AVNS for comparison